Adrb2 (adrenoceptor beta 2) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Adrb2 (adrenoceptor beta 2) Rattus norvegicus
Symbol: Adrb2
Name: adrenoceptor beta 2
RGD ID: 2060
Description: Enables several functions, including G-protein alpha-subunit binding activity; beta2-adrenergic receptor activity; and signaling receptor binding activity. Involved in several processes, including chemical synaptic transmission; positive regulation of monoatomic ion transport; and response to steroid hormone. Located in several cellular components, including caveola; neuronal cell body membrane; and sarcolemma. Is active in Schaffer collateral - CA1 synapse; glutamatergic synapse; and postsynaptic membrane. Used to study cardiomyopathy (multiple); congestive heart failure; kidney disease (multiple); and lung disease (multiple). Biomarker of several diseases, including acute kidney failure; artery disease (multiple); congestive heart failure; polycystic ovary syndrome; and ulcerative colitis. Human ortholog(s) of this gene implicated in several diseases, including autoimmune disease (multiple); disease of metabolism (multiple); kidney failure (multiple); lung disease (multiple); and open-angle glaucoma (multiple). Orthologous to human ADRB2 (adrenoceptor beta 2); PARTICIPATES IN G protein mediated signaling pathway via Galphai family; adrenergic beta receptor agonist and beta-blocker pharmacodynamics pathway; epinephrine signaling pathway via adrenergic receptor beta; INTERACTS WITH (5-hydroxyindol-3-yl)acetic acid; (R)-adrenaline; (R)-noradrenaline.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: Adrenergic beta 2- receptor surface; adrenergic receptor, beta 2; adrenergic, beta-2-, receptor, surface; adrenoceptor beta 2, surface; beta-2 adrenergic receptor; beta-2 adrenoceptor; beta-2 adrenoreceptor
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Is Marker For: QTLs:   BpQTLcluster15  
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21855,642,459 - 55,644,501 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1855,502,903 - 55,644,512 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1857,735,062 - 57,737,132 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01858,450,067 - 58,452,145 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01856,266,287 - 56,268,329 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01857,513,792 - 57,515,834 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1857,513,793 - 57,515,834 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01856,739,990 - 56,742,032 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41858,174,958 - 58,177,000 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11858,247,190 - 58,249,232 (-)NCBI
Celera1853,789,848 - 53,791,890 (-)NCBICelera
RH 3.4 Map18542.9RGD
Cytogenetic Map18q12.1NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
acute kidney failure  (IEP,IMP,ISO)
AIDS Dementia Complex  (ISO)
Angina Pectoris  (ISO)
asthma  (ISO)
autism spectrum disorder  (ISO)
autistic disorder  (ISO)
Breast Neoplasms  (ISO)
bronchiolitis  (ISO)
cardiomyopathy  (ISO)
cardiovascular system disease  (ISO)
cholangiocarcinoma  (ISO)
chronic obstructive pulmonary disease  (ISO)
congestive heart failure  (IDA,IEP,ISO)
Coronary Disease  (ISO)
cystic fibrosis  (ISO)
dermatitis  (ISO)
dilated cardiomyopathy  (IDA,ISO)
disease of metabolism  (ISO)
end stage renal disease  (ISO)
Experimental Liver Cirrhosis  (IEP)
familial adenomatous polyposis 1  (ISO)
familial hyperlipidemia  (ISO)
fatty liver disease  (ISO)
Fibrosis  (ISO)
genetic disease  (ISO)
Graves' disease  (ISO)
Hereditary Neoplastic Syndromes  (ISO)
human immunodeficiency virus infectious disease  (ISO)
Hyperlipoproteinemia Type II  (ISO)
hypertension  (IEP,ISO)
Hypertriglyceridemia  (ISO)
hypokalemia  (ISO)
hypothyroidism  (IEP)
Insulin Resistance  (IDA,ISO)
interstitial cystitis  (ISO)
kidney disease  (IMP)
Left Ventricular Hypertrophy  (ISO)
Liver Injury  (IEP)
lung disease  (ISO)
Metabolic Syndrome  (ISO)
myasthenia gravis  (ISO)
myocardial infarction  (IEP,ISO)
Myocardial Ischemia  (ISO)
Myocardial Reperfusion Injury  (IDA)
myocarditis  (IMP)
Nasal Polyps  (ISO)
nervous system disease  (ISO)
Neurodevelopmental Disorders  (ISO)
obesity  (ISO)
open-angle glaucoma  (ISO)
Paroxysmal Dyspnea  (ISO)
pneumonia  (IDA)
polycystic ovary syndrome  (IEP)
primary open angle glaucoma  (ISO)
Prostatic Neoplasms  (ISO)
psoriasis  (ISO)
pulmonary edema  (IMP,ISO)
Reperfusion Injury  (IDA)
sciatic neuropathy  (ISO)
Sepsis  (IDA,IEP)
Stomach Neoplasms  (ISO)
toxic shock syndrome  (ISO)
Tremor  (ISO)
type 2 diabetes mellitus  (ISO)
ulcerative colitis  (IEP)
urticaria  (ISO)
Ventricular Dysfunction, Left  (ISO)
Vestibulocochlear Nerve Injuries  (IEP)
viral encephalitis  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(-)-epigallocatechin 3-gallate  (ISO)
(5-hydroxyindol-3-yl)acetic acid  (EXP)
(R)-adrenaline  (EXP,ISO)
(R)-noradrenaline  (EXP,ISO)
(R)-octopamine  (ISO)
(S)-nicotine  (ISO)
(S)-timolol (anhydrous)  (ISO)
1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)-2-propanol  (ISO)
1-nitropyrene  (ISO)
15-acetyldeoxynivalenol  (ISO)
17alpha-ethynylestradiol  (EXP)
17beta-estradiol  (ISO)
17beta-hydroxy-5alpha-androstan-3-one  (ISO)
1H-imidazole  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (ISO)
2,4-dibromophenyl 2,4,5-tribromophenyl ether  (ISO)
2-(tert-butylamino)-1-(2-chlorophenyl)ethanol  (ISO)
2-hydroxypropanoic acid  (ISO)
3',5'-cyclic AMP  (EXP,ISO)
3,3',4,4',5-pentachlorobiphenyl  (EXP)
3,3',5-triiodo-L-thyronine  (ISO)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
4,4'-sulfonyldiphenol  (EXP)
4-hydroxynon-2-enal  (ISO)
5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-azacytidine  (ISO)
6-propyl-2-thiouracil  (EXP)
acebutolol  (ISO)
acetamide  (EXP)
acetylsalicylic acid  (ISO)
acrylamide  (EXP)
actinomycin D  (ISO)
aflatoxin B1  (EXP,ISO)
albuterol  (EXP,ISO)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (ISO)
alprenolol  (ISO)
amiodarone  (ISO)
ammonium chloride  (EXP)
aristolochic acid A  (ISO)
arsenite(3-)  (ISO)
asbestos  (ISO)
atenolol  (EXP,ISO)
bambuterol  (ISO)
beclomethasone  (ISO)
befunolol  (ISO)
benazepril  (ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
Benzo[k]fluoranthene  (ISO)
betaxolol  (ISO)
bexarotene  (ISO)
bicalutamide  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisoprolol  (EXP,ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (EXP)
bitolterol  (ISO)
bosentan  (ISO)
budesonide  (ISO)
busulfan  (ISO)
butanal  (ISO)
cadmium dichloride  (ISO)
calcitriol  (ISO)
calcium atom  (EXP,ISO)
calcium(0)  (EXP,ISO)
carbon nanotube  (ISO)
carteolol  (ISO)
carvedilol  (EXP,ISO)
CGP 12177  (EXP,ISO)
CGP 52608  (ISO)
chlorpyrifos  (EXP,ISO)
choline  (ISO)
cisplatin  (ISO)
clenbuterol  (EXP,ISO)
clobenpropit  (ISO)
clofibrate  (ISO)
clorgyline  (ISO)
clorprenaline  (ISO)
clothianidin  (ISO)
cobalt atom  (ISO)
colforsin daropate hydrochloride  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
corticosterone  (EXP)
crocidolite asbestos  (ISO)
crotonaldehyde  (ISO)
cycloheximide  (ISO)
cyclosporin A  (ISO)
D-glucose  (ISO)
dexamethasone  (EXP,ISO)
dextran sulfate  (ISO)
diazinon  (EXP)
dibenz[a,h]anthracene  (ISO)
dichlorine  (EXP)
diclofenac  (ISO)
dieldrin  (EXP)
diethylstilbestrol  (EXP)
dimethylarsinic acid  (ISO)
dioxygen  (EXP,ISO)
dobutamine  (ISO)
dopamine  (EXP)
dorsomorphin  (ISO)
doxazosin  (EXP)
doxorubicin  (ISO)
enalaprilat dihydrate  (EXP)
endosulfan  (EXP)
ethanol  (EXP,ISO)
fenamidone  (ISO)
fenoterol  (EXP,ISO)
fipronil  (ISO)
folic acid  (ISO)
fonofos  (ISO)
formoterol fumarate  (ISO)
furan  (EXP)
glucose  (ISO)
gold atom  (ISO)
gold(0)  (ISO)
hexane  (ISO)
histamine  (EXP,ISO)
ICI 118551  (EXP,ISO)
imipramine  (ISO)
Immepip  (ISO)
indacaterol  (ISO)
iodocyanopindolol  (EXP,ISO)
isoprenaline  (EXP,ISO)
ketoconazole  (EXP)
ketotifen  (ISO)
L-methionine  (ISO)
labetalol  (EXP,ISO)
Licochalcone B  (ISO)
lipopolysaccharide  (EXP,ISO)
losartan  (EXP)
metaproterenol  (ISO)
methimazole  (EXP)
methotrexate  (ISO)
methoxychlor  (EXP)
methylarsonic acid  (ISO)
methylisothiazolinone  (ISO)
metoprolol  (EXP,ISO)
mifepristone  (EXP)
miquelianin  (ISO)
N,N-diethyl-m-toluamide  (ISO)
nadolol  (ISO)
nickel atom  (EXP)
nicotine  (ISO)
nitric oxide  (ISO)
octopamine  (ISO)
olodaterol  (ISO)
orciprenaline  (ISO)
orphenadrine  (EXP)
ozone  (EXP,ISO)
paracetamol  (EXP,ISO)
parathion  (ISO)
pentanal  (ISO)
perfluorooctanoic acid  (EXP)
phenylephrine  (EXP)
phorbol 13-acetate 12-myristate  (ISO)
picrotoxin  (EXP)
pindolol  (EXP,ISO)
Pirbuterol  (ISO)
pirinixic acid  (ISO)
potassium atom  (ISO)
potassium chromate  (ISO)
practolol  (ISO)
progesterone  (EXP)
propafenone  (ISO)
propanal  (ISO)
propranolol  (EXP,ISO)
propranolol hydrochloride  (EXP)
prostaglandin E1  (ISO)
prostaglandin E2  (ISO)
putrescine  (ISO)
rac-lactic acid  (ISO)
ractopamine  (ISO)
reproterol  (ISO)
reserpine  (EXP)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
Salmeterol xinafoate  (EXP,ISO)
SB 431542  (ISO)
silicon dioxide  (ISO)
sodium arsenate  (ISO)
sodium arsenite  (ISO)
sodium atom  (EXP)
sodium dodecyl sulfate  (ISO)
sotalol  (ISO)
sotorasib  (ISO)
spermidine  (ISO)
spermine  (ISO)
streptozocin  (EXP)
sulfadimethoxine  (EXP)
sunitinib  (ISO)
synephrine  (EXP)
tamoxifen  (ISO)
terbufos  (ISO)
terbutaline  (EXP,ISO)
tetrachloroethene  (ISO)
thioacetamide  (EXP)
titanium dioxide  (ISO)
trametinib  (ISO)
tributylstannane  (ISO)
trichloroethene  (EXP)
trichostatin A  (ISO)
triclosan  (ISO)
trovafloxacin  (ISO)
tungsten  (ISO)
valproic acid  (ISO)
vilanterol  (ISO)
vincristine  (ISO)
vorinostat  (ISO)
Zilpaterol  (ISO)
zinc atom  (ISO)
zinc(0)  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
adenylate cyclase-activating adrenergic receptor signaling pathway  (IBA)
adenylate cyclase-activating G protein-coupled receptor signaling pathway  (IDA,IEA,ISO)
adrenergic receptor signaling pathway  (IEA,ISO)
associative learning  (IDA)
blood vessel diameter maintenance  (IEA)
bone resorption  (IEA,ISO)
brown fat cell differentiation  (IEA,ISO)
cellular response to amyloid-beta  (IEA,ISO)
cellular response to hypoxia  (IDA)
diaphragm contraction  (IDA)
diet induced thermogenesis  (IEA,ISO)
estrous cycle  (IEP)
excitatory postsynaptic potential  (IMP)
female pregnancy  (IEP)
G protein-coupled receptor signaling pathway  (IDA)
heat generation  (IEA,ISO)
liver development  (IEP)
liver regeneration  (IEP)
negative regulation of angiogenesis  (IMP)
negative regulation of interleukin-6 production  (ISO)
negative regulation of multicellular organism growth  (IEA,ISO)
negative regulation of ossification  (IMP)
negative regulation of smooth muscle contraction  (IBA,IEA,ISO)
negative regulation of tumor necrosis factor production  (ISO)
negative regulation of urine volume  (IMP)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure  (IBA,IEA,ISO)
positive regulation of apoptotic process  (IMP)
positive regulation of ATP-dependent activity  (IMP)
positive regulation of autophagosome maturation  (IEA,ISO,ISS)
positive regulation of bone mineralization  (IEA,ISO)
positive regulation of calcium ion import across plasma membrane  (IDA)
positive regulation of cell population proliferation  (IDA)
positive regulation of cold-induced thermogenesis  (IEA,ISO,ISS)
positive regulation of lipophagy  (IEA,ISO,ISS)
positive regulation of MAPK cascade  (IEA,ISO)
positive regulation of mini excitatory postsynaptic potential  (IEA,ISO)
positive regulation of potassium ion transport  (IDA)
positive regulation of protein kinase A signaling  (IEA,ISO)
positive regulation of skeletal muscle tissue growth  (IMP)
positive regulation of sodium ion transport  (IDA)
positive regulation of the force of heart contraction by epinephrine  (IDA)
positive regulation of transcription by RNA polymerase II  (IEA,ISO)
presynaptic modulation of chemical synaptic transmission  (EXP,IDA)
receptor-mediated endocytosis  (IEA,ISO)
regulation of calcium ion transport  (IDA)
regulation of smooth muscle contraction  (IEA)
regulation of sodium ion transport  (IEA,ISO)
regulation of systemic arterial blood pressure by norepinephrine-epinephrine  (ISO)
regulation of vein smooth muscle contraction  (IDA)
response to catecholamine  (IDA)
response to cold  (IEA,ISO)
response to dexamethasone  (IEP)
response to estrogen  (IEP)
response to hypoxia  (IEP)
response to monoamine  (IEP)
response to progesterone  (IEP)
response to testosterone  (IEP)
smooth muscle contraction  (IEA,ISO)
synaptic transmission, glutamatergic  (IMP)
transcription by RNA polymerase II  (IEA,ISO)
vasodilation  (IDA)

Cellular Component


References - curated
# Reference Title Reference Citation
1. Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction. Ahmet I, etal., J Pharmacol Exp Ther. 2008 May;325(2):491-9. Epub 2008 Feb 20.
2. Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. Ahmet I, etal., J Pharmacol Exp Ther. 2009 Oct;331(1):178-85. Epub 2009 Jul 8.
3. Distribution of the beta-2 adrenergic receptor messenger RNA in the rat brain by in situ hybridization histochemistry: effects of chronic reserpine treatment. Asanuma M, etal., Neurochem Res. 1991 Dec;16(12):1253-6.
4. betaAR signaling required for diet-induced thermogenesis and obesity resistance. Bachman ES, etal., Science 2002 Aug 2;297(5582):843-5.
5. Transcriptional and posttranscriptional regulation of hepatic beta 2-adrenergic receptor gene expression during development. Baeyens DA and Cornett LE, J Cell Physiol. 1993 Oct;157(1):70-6.
6. In vitro hypoxia impairs beta2-adrenergic receptor signaling in primary rat alveolar epithelial cells. Baloglu E, etal., Am J Physiol Lung Cell Mol Physiol. 2009 Mar;296(3):L500-9. doi: 10.1152/ajplung.90390.2008. Epub 2008 Dec 19.
7. beta2-Adrenergics in hypoxia desensitize receptors but blunt inhibition of reabsorption in rat lungs. Baloglu E, etal., Am J Respir Cell Mol Biol. 2011 Nov;45(5):1059-68. Epub 2011 May 11.
8. Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. Basu K, etal., J Allergy Clin Immunol. 2009 Dec;124(6):1188-94.e3. Epub .
9. The genetic association database. Becker KG, etal., Nat Genet. 2004 May;36(5):431-2.
10. Alteration of trabecular bone under chronic beta2 agonists treatment. Bonnet N, etal., Med Sci Sports Exerc. 2005 Sep;37(9):1493-501.
11. beta1, beta2, and beta3 adrenoceptors and Na+/H+ exchanger regulatory factor 1 expression in human bronchi and their modifications in cystic fibrosis. Bossard F, etal., Am J Respir Cell Mol Biol. 2011 Jan;44(1):91-8. Epub 2010 Mar 4.
12. beta2-Adrenergic receptor stimulation in vivo induces apoptosis in the rat heart and soleus muscle. Burniston JG, etal., J Appl Physiol. 2005 Apr;98(4):1379-86. Epub 2004 Dec 10.
13. Argl6gly polymorphism of the beta2-adrenoceptor gene (ADRBeta2) as a susceptibility factor for nasal polyposis. Bussu F, etal., Am J Rhinol. 2007 May-Jun;21(3):378-82.
14. Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Carroll CL, etal., Chest. 2009 May;135(5):1186-92. Epub 2008 Nov 24.
15. Attenuation of insulin resistance by chronic beta2-adrenergic agonist treatment possible muscle specific contributions. Castle A, etal., Life Sci. 2001 Jun 22;69(5):599-611.
16. Opposite action of beta1- and beta2-adrenergic receptors on Ca(V)1 L-channel current in rat adrenal chromaffin cells. Cesetti T, etal., J Neurosci 2003 Jan 1;23(1):73-83.
17. Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. Chen Y, etal., Am J Nephrol. 2010;32(1):23-30. Epub 2010 May 19.
18. Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment. Choucair-Jaafar N, etal., Br J Pharmacol. 2009 Dec;158(7):1683-94. doi: 10.1111/j.1476-5381.2009.00510.x. Epub .
19. Inotropy and L-type Ca2+ current, activated by beta1- and beta2-adrenoceptors, are differently controlled by phosphodiesterases 3 and 4 in rat heart. Christ T, etal., Br J Pharmacol. 2009 Jan;156(1):62-83.
20. Beta 2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K-transport in rat soleus muscle. Clausen T and Flatman JA, Br J Pharmacol. 1980 Apr;68(4):749-55.
21. Analysis of the beta 1 and beta 2 adrenoceptor interactions of the partial agonist, clenbuterol (NAB365), in the rat jugular vein and atria. Cohen ML, etal., Naunyn Schmiedebergs Arch Pharmacol. 1982 Aug;320(2):145-51.
22. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein. Communal C, etal., Circulation. 1999 Nov 30;100(22):2210-2.
23. Effect of ageing and propranolol administration on myocardial beta-adrenoceptor receptor function in mature rats. Conlon D, etal., Eur J Pharmacol. 1995 Apr 28;289(2):283-90.
24. The Gly16-->Arg16 and Gln27-->Glu27 polymorphisms of beta2-adrenergic receptor are associated with metabolic syndrome in men. Dallongeville J, etal., J Clin Endocrinol Metab. 2003 Oct;88(10):4862-6.
25. A beta2 adrenergic receptor signaling complex assembled with the Ca2+ channel Cav1.2. Davare MA, etal., Science. 2001 Jul 6;293(5527):98-101.
26. Different genes and polymorphisms affecting high-density lipoprotein cholesterol levels in greek familial hypercholesterolemia patients. Dedoussis GV, etal., Genet Test. 2006 Fall;10(3):192-9.
27. Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. Dello Russo C, etal., J Neuroinflammation. 2004 Jun 30;1(1):9.
28. Safety and efficacy of beta agonists. Donohue JF Respir Care. 2008 May;53(5):618-22; discussion 623-4.
29. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. Dorow P, etal., J Cardiovasc Pharmacol. 1990;16 Suppl 5:S36-44.
30. Beta-adrenergic stimulation and myocardial function in the failing heart. El-Armouche A and Eschenhagen T, Heart Fail Rev. 2009 Dec;14(4):225-41.
31. Desensitization of beta2-adrenoceptor function in non-pregnant rat myometrium is modulated by sex steroids. Engstrom T, etal., J Endocrinol. 2001 Jul;170(1):147-55.
32. Role of beta2-adrenoceptor-beta-arrestin2-nuclear factor-kappaB signal transduction pathway and intervention effects of oxymatrine in ulcerative colitis. Fan H, etal., Chin J Integr Med. 2012 Jul;18(7):514-21. Epub 2012 Jul 7.
33. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. Feldman G, etal., BMC Pulm Med. 2010 Mar 8;10:11.
34. Effects of uremic plasma on alpha- and beta-adrenoceptor subtypes. Ferchland A, etal., Nephron. 1998 Sep;80(1):46-50.
35. Nitric oxide-dependent beta2-adrenergic dilatation of rat aorta is mediated through activation of both protein kinase A and Akt. Ferro A, etal., Br J Pharmacol. 2004 Oct;143(3):397-403. Epub 2004 Sep 6.
36. beta-Adrenergic blockers: a 50-year historical perspective. Frishman WH Am J Ther. 2008 Nov-Dec;15(6):565-76.
37. Involvement of beta2-adrenergic and mu-opioid receptors in antinociception produced by intracerebroventricular administration of alpha,beta-methylene-ATP. Fukui M, etal., Jpn J Pharmacol. 2001 Aug;86(4):423-8.
38. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
39. Inhaled corticosteroids and long-acting beta 2-agonists in treatment of patients with chronic bronchiolitis following exposure to sulfur mustard. Ghanei M, etal., Inhal Toxicol. 2007 Aug;19(10):889-94.
40. Studies of the associations between functional beta(2)-adrenergic receptor variants and obesity, hypertension and type 2 diabetes in 7,808 white subjects. Gjesing AP, etal., Diabetologia. 2007 Mar;50(3):563-8. Epub 2007 Jan 13.
41. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
42. Primary structure of rat cardiac beta-adrenergic and muscarinic cholinergic receptors obtained by automated DNA sequence analysis: further evidence for a multigene family. Gocayne J, etal., Proc Natl Acad Sci U S A 1987 Dec;84(23):8296-300.
43. Cellular and subcellular distributions of beta1- and beta2-adrenoceptors in the CA1 and CA3 regions of the rat hippocampus. Guo NN and Li BM, Neuroscience. 2007 Apr 25;146(1):298-305. Epub 2007 Mar 2.
44. Hypertension genes are genetic markers for insulin sensitivity and resistance. Guo X, etal., Hypertension. 2005 Apr;45(4):799-803. Epub 2005 Feb 7.
45. A novel bioassay for detecting GPCR heterodimerization: transactivation of beta 2 adrenergic receptor by bradykinin receptor. Haack KK, etal., J Biomol Screen. 2010 Mar;15(3):251-60. doi: 10.1177/1087057109360254. Epub 2010 Feb 11.
46. G-protein-coupled receptor signaling components localize in both sarcolemmal and intracellular caveolin-3-associated microdomains in adult cardiac myocytes. Head BP, etal., J Biol Chem. 2005 Sep 2;280(35):31036-44. Epub 2005 Jun 16.
47. Beta2-adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Heckbert SR, etal., Circulation. 2003 Apr 22;107(15):2021-4. Epub 2003 Apr 7.
48. Dynamics of beta2-adrenergic receptor-ligand complexes on living cells. Hegener O, etal., Biochemistry. 2004 May 25;43(20):6190-9.
49. Repeated bouts of moderate-intensity aerobic exercise reduce airway reactivity in a murine asthma model. Hewitt M, etal., Am J Respir Cell Mol Biol. 2010 Feb;42(2):243-9. Epub 2009 May 7.
50. beta 1-adrenergic receptor association with PSD-95. Inhibition of receptor internalization and facilitation of beta 1-adrenergic receptor interaction with N-methyl-D-aspartate receptors. Hu LA, etal., J Biol Chem. 2000 Dec 8;275(49):38659-66.
51. Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension. Iaccarino G, etal., Clin Pharmacol Ther. 2006 Dec;80(6):633-45.
52. Polymorphism of beta-adrenergic receptors and susceptibility to open-angle glaucoma. Inagaki Y, etal., Mol Vis. 2006 Jun 12;12:673-80.
53. Polymorphic variants of the beta2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population. Isaza C, etal., Methods Find Exp Clin Pharmacol. 2005 May;27(4):237-44.
54. A selective beta2-adrenergic agonist, terbutaline, improves sepsis-induced diaphragmatic dysfunction in the rat. Ito T, etal., Life Sci. 2006 Jul 24;79(9):905-12. Epub 2006 Apr 17.
55. Gln27Glu beta2-adrenergic receptor variant is associated with hypertriglyceridemia and the development of fatty liver. Iwamoto N, etal., Clin Chim Acta. 2001 Dec;314(1-2):85-91.
56. beta-2-adrenergic receptor gene polymorphism confers susceptibility to Graves disease. Jazdzewski K, etal., Int J Mol Med. 2007 Jan;19(1):181-6.
57. Sequence of the 5' regulatory domain of the gene encoding the rat beta 2-adrenergic receptor. Jiang L and Kunos G, Gene 1995 Oct 3;163(2):331-2.
58. DNA elements and protein factors involved in the transcription of the beta 2-adrenergic receptor gene in rat liver. The negative regulatory role of C/EBP alpha. Jiang L, etal., Biochemistry. 1996 Oct 8;35(40):13136-46.
59. Beta(1)/beta(2)/beta(3)-adrenoceptor knockout mice are obese and cold-sensitive but have normal lipolytic responses to fasting. Jimenez M, etal., FEBS Lett. 2002 Oct 23;530(1-3):37-40.
60. Synthesis, beta-adrenergic blocking activity and beta-receptor binding affinities of 1-substituted-3-(2-isopropyl-5-methyl-phenoxy)-propan-2-ol oxalates. Jindal DP, etal., Farmaco. 2003 Aug;58(8):557-62.
61. Assembly of a beta2-adrenergic receptor--GluR1 signalling complex for localized cAMP signalling. Joiner ML, etal., EMBO J. 2010 Jan 20;29(2):482-95. Epub 2009 Nov 26.
62. Alpha1-and beta2-adrenoceptors in the human liver with mass-forming intrahepatic cholangiocarcinoma: density and coupling to adenylate cyclase and phospholipase C. Kassahun WT, etal., Naunyn Schmiedebergs Arch Pharmacol. 2005 Nov;372(3):171-81. Epub 2005 Nov 15.
63. Platelet beta-adrenoceptors. Kerry R and Scrutton MC, Br J Pharmacol. 1983 Jul;79(3):681-91.
64. Association of beta 2-adrenergic receptor polymorphism with the phenotype of aspirin-intolerant acute urticaria. Kim HA, etal., Yonsei Med J. 2007 Dec 31;48(6):1079-81.
65. Association of COPD candidate genes with CT emphysema and airway phenotypes in severe COPD. Kim WJ, etal., Eur Respir J. 2010 Jun 4.
66. CT scanning-based phenotypes vary with ADRB2 polymorphisms in chronic obstructive pulmonary disease. Kim WJ, etal., Respir Med. 2009 Jan;103(1):98-103. Epub 2008 Sep 11.
67. Changes in beta-2 adrenergic receptor and AMP-activated protein kinase alpha-2 subunit in the rat vestibular nerve after labyrinthectomy. Kitahara T, etal., Neurosci Res. 2012 Mar;72(3):221-6. doi: 10.1016/j.neures.2011.11.007. Epub 2011 Dec 8.
68. High-density rat radiation hybrid maps containing over 24,000 SSLPs, genes, and ESTs provide a direct link to the rat genome sequence. Kwitek AE, etal., Genome Res. 2004 Apr;14(4):750-7
69. beta(2)-Adrenoceptor-mediated facilitation of glutamatergic transmission in rat ventromedial hypothalamic neurons. Lee JG, etal., Neuroscience. 2007 Feb 23;144(4):1255-65. Epub 2006 Dec 18.
70. Assembly of a Ca2+-dependent BK channel signaling complex by binding to beta2 adrenergic receptor. Liu G, etal., EMBO J. 2004 Jun 2;23(11):2196-205. Epub 2004 May 13.
71. [Dynamic changes of alpha-AR, beta1-AR and beta2-AR expression during hepatic fibrogenesis]. Liu N, etal., Zhonghua Gan Zang Bing Za Zhi. 2009 Sep;17(9):653-6.
72. A46G and C79G polymorphisms in the beta2-adrenergic receptor gene (ADRB2) and essential hypertension risk: a meta-analysis. Lou Y, etal., Hypertens Res. 2010 Aug 26.
73. Combined therapy of pentastarch, dexamethasone, and dibutyryl-cAMP or beta 2-agonist attenuates ischaemia/reperfusion injury of rat lung. Lu HL and Chiang CH, Injury. 2008 Sep;39(9):1062-70. Epub 2008 Mar 11.
74. Tumor necrosis factor-alpha mediates the proliferation of rat C6 glioma cells via beta-adrenergic receptors. Lung HL, etal., J Neuroimmunol. 2005 Sep;166(1-2):102-12.
75. Increased reabsorption of alveolar edema fluid in the obese Zucker rat. Ma G, etal., Tohoku J Exp Med. 2008 Nov;216(3):223-30.
76. Ovarian expression of alpha (1)- and beta (2)-adrenoceptors and p75 neurotrophin receptors in rats with steroid-induced polycystic ovaries. Manni L, etal., Auton Neurosci. 2005 Mar 31;118(1-2):79-87.
77. Characterization, expression, and hormonal control of a thymic beta 2-adrenergic receptor. Marchetti B, etal., Am J Physiol. 1994 Nov;267(5 Pt 1):E718-31.
78. Castration levels of plasma testosterone have potent stimulatory effects on androgen-sensitive parameters in the rat prostate. Marchetti B, etal., J Steroid Biochem. 1988 Oct;31(4A):411-9.
79. Beta2-adrenoceptor polymorphisms predict response to beta2-agonists in children with acute asthma. Martin AC, etal., J Asthma. 2008 Jun;45(5):383-8.
80. Beta2-adrenoceptor polymorphisms relate to obesity through blunted leptin-mediated sympathetic activation. Masuo K, etal., Am J Hypertens. 2006 Oct;19(10):1084-91.
81. Temporal dynamics of inotropic, chronotropic, and metabolic responses during beta1- and beta2-AR stimulation in the isolated, perfused rat heart. McConville P, etal., Am J Physiol Endocrinol Metab. 2005 Sep;289(3):E412-8. Epub 2005 Apr 19.
82. Regulation of the beta 2-adrenergic receptor and its mRNA in the rat lung by dexamethasone. McGraw DW, etal., Exp Lung Res. 1995 Jul-Aug;21(4):535-46.
83. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
84. Alpha and beta-adrenoceptors in hypertension. I. Cardiac and renal alpha 1-, beta 1-, and beta 2-adrenoceptors in rat models of acquired hypertension. Michel MC, etal., J Cardiovasc Pharmacol. 1989 Mar;13(3):421-31.
85. Potent adenylate cyclase agonist forskolin restores myoprotective effects of ischemic preconditioning in rat hearts after myocardial infarction. Mieno S, etal., Ann Thorac Surg. 2002 Oct;74(4):1213-8.
86. Activation of beta2-adrenergic receptor plays a pivotal role in generating the protective effect of ischemic preconditioning in rat hearts. Mieno S, etal., Scand Cardiovasc J. 2005 Oct;39(5):313-9.
87. Immunocytochemical localization of beta2-adrenergic receptors in the rat spinal cord and their spatial relationships to tyrosine hydroxylase-immunoreactive terminals. Mizukami T Kurume Med J. 2004;51(3-4):175-83.
88. Beta2-adrenergic receptor haplotype and bronchodilator response to salbutamol in patients with acute exacerbations of COPD. Mokry M, etal., Med Sci Monit. 2008 Aug;14(8):CR392-8.
89. beta(2)-adrenergic receptor promoter haplotype influences spirometric response during an acute asthma exacerbation. Moore PE, etal., Clin Transl Sci. 2008 Sep;1(2):155-61.
90. beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. Nakada TA, etal., Am J Respir Crit Care Med. 2010 Jan 15;181(2):143-9. doi: 10.1164/rccm.200903-0332OC. Epub 2009 Oct 22.
91. Adenoviral delivery of the beta2-adrenoceptor gene in sepsis: a subcutaneous approach in rat for kidney protection. Nakamura A, etal., Clin Sci (Lond). 2005 Dec;109(6):503-11.
92. Renal beta(2)-adrenoceptor modulates the lipopolysaccharide transport system in sepsis-induced acute renal failure. Nakamura A, etal., Inflammation. 2009 Feb;32(1):12-9.
93. beta(2)-Adrenoceptor activation attenuates endotoxin-induced acute renal failure. Nakamura A, etal., J Am Soc Nephrol. 2004 Feb;15(2):316-25.
94. Renal beta2-adrenoceptor blockade worsens the outcome of an induced Escherichia coli renal infection. Nakamura A, etal., J Nephrol. 2010 May-Jun;23(3):341-9.
95. Protection from sepsis-induced acute renal failure by adenoviral-mediated gene transfer of beta2-adrenoceptor. Nakamura A, etal., Nephrol Dial Transplant. 2010 Mar;25(3):730-7. Epub 2009 Nov 3.
96. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
97. Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Nikolaev VO, etal., Science. 2010 Mar 26;327(5973):1653-7. Epub 2010 Feb 25.
98. Beta2-Adrenergic agonists suppress rat autoimmune myocarditis: potential role of beta2-adrenergic stimulants as new therapeutic agents for myocarditis. Nishii M, etal., Circulation. 2006 Aug 29;114(9):936-44. Epub 2006 Aug 14.
99. Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthma. O'Byrne PM, etal., J Allergy Clin Immunol. 2009 Dec;124(6):1217-21.
100. Beta-adrenergic receptor trafficking by exercise in rat adipocytes: roles of G-protein-coupled receptor kinase-2, beta-arrestin-2, and the ubiquitin-proteasome pathway. Ogasawara J, etal., FASEB J. 2006 Feb;20(2):350-2. Epub 2005 Dec 20.
101. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
102. Association of the Arg16Gly polymorphism of the beta-2-adrenergic receptor with psoriasis. Ozkur M, etal., J Dermatol Sci. 2004 Aug;35(2):162-4.
103. Development of novel microarray methodology for the study of mutations in the SERPINA1 and ADRB2 genes--their association with Obstructive Pulmonary Disease and Disseminated Bronchiectasis in Greek patients. Papatheodorou A, etal., Clin Biochem. 2010 Jan;43(1-2):43-50. Epub 2009 Sep 10.
104. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
105. Beta-adrenergic receptor subtype gene expression in timed-pregnant rat myometrium. Principe D, etal., Am J Obstet Gynecol. 1997 Feb;176(2):349-57.
106. beta2AR antagonists and beta2AR gene deletion both promote skin wound repair processes. Pullar CE, etal., J Invest Dermatol. 2012 Aug;132(8):2076-84. doi: 10.1038/jid.2012.108. Epub 2012 Apr 12.
107. [Association between beta2-adrenergic receptor haplotype/polymorphisms and asthma phenotype] Qiu YY and Yin KS, Zhonghua Jie He He Hu Xi Za Zhi. 2008 Mar;31(3):201-5.
108. beta2-Adrenergic receptor responsiveness of the calpain-calpastatin system and attenuation of neuronal death in rat hippocampus after transient global ischemia. Rami A, etal., Neurosci Res. 2003 Dec;47(4):373-82.
109. Adenylosuccinate lyase as an indicator of breast and prostate malignancies: a preliminary report. Reed VL, etal., Clin Biochem. 1987 Oct;20(5):349-51.
110. Changes in beta 1- and beta 2-adrenergic receptor mRNA levels in brown adipose tissue and heart of hypothyroid rats. Revelli JP, etal., Biochem J. 1991 Aug 1;277 ( Pt 3):625-9.
111. GOA pipeline RGD automated data pipeline
112. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
113. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
114. Intrinsic atopic dermatitis is associated with a beta-2 adrenergic receptor polymorphism. Roguedas AM, etal., Acta Derm Venereol. 2006;86(5):447-8.
115. beta-1 and beta-2, but not alpha-1 and alpha-2, adrenoceptor blockade delays rat cutaneous wound healing. Romana-Souza B, etal., Wound Repair Regen. 2009 Mar-Apr;17(2):230-9.
116. Beta-adrenoreceptors in rat brown adipose tissue: proportions of beta 1- and beta 2-subtypes. Rothwell NJ, etal., Am J Physiol. 1985 Apr;248(4 Pt 1):E397-402.
117. Interactions of epinephrine, norepinephrine, dopamine and their corresponding alpha-methyl-substituted derivatives with alpha and beta adrenoceptors in the pithed rat. Ruffolo RR Jr, etal., J Pharmacol Exp Ther. 1984 Sep;230(3):595-600.
118. The specific binding of broxaterol, a new beta 2-selective agonist, to beta-adrenoceptors. Sala R, etal., Eur J Pharmacol. 1991 Oct 2;203(1):17-23.
119. 164Ile allele in the beta2-Adrenergic receptor gene is associated with risk of elevated blood pressure in women. The Copenhagen City Heart Study. Sethi AA, etal., Pharmacogenet Genomics. 2005 Sep;15(9):633-45.
120. Comparison of beta adrenergic receptor binding characteristics and coupling to adenylate cyclase in rat pulmonary artery versus aorta. Shaul PW, etal., J Pharmacol Exp Ther. 1990 Jan;252(1):86-92.
121. Beta 2-adrenergic function in cultured rat proximal tubule epithelial cells. Singh H and Linas S, Am J Physiol. 1996 Jul;271(1 Pt 2):F71-7.
122. Effects of some beta-adrenoceptor blockers on avoidance learning in rats. Staneva-Stoytcheva D, etal., Methods Find Exp Clin Pharmacol. 1989 Sep;11(9):535-40.
123. Beta-2-adrenergic receptor polymorphisms in cystic fibrosis. Steagall WK, etal., Pharmacogenet Genomics. 2007 Jun;17(6):425-30.
124. Probable role of beta2-adrenergic receptor gene haplotype in high-altitude pulmonary oedema. Stobdan T, etal., Respirology. 2010 May;15(4):651-8.
125. Molecular analysis of adrenergic receptor genes and interleukin-4/interleukin-4 receptor genes in patients with interstitial cystitis. Sugaya K, etal., J Urol. 2002 Dec;168(6):2668-71.
126. Real-time imaging of green fluorescent protein-tagged beta 2-adrenergic receptor distribution in living cells. Sunaguchi M, etal., Brain Res. 2003 Sep 12;984(1-2):21-32.
127. Role of ADRB2 gene polymorphism in asthma and response to beta(2)-agonists in Polish children. Szczepankiewicz A, etal., J Appl Genet. 2009;50(3):275-81.
128. Decreased beta 2-adrenergic receptor-mRNA and loricrin-mRNA, and increased involucrin-mRNA transcripts in psoriatic epidermis: analysis by reverse transcription-polymerase chain reaction. Takahashi H, etal., Br J Dermatol. 1996 Jun;134(6):1065-9.
129. Effects of beta 1- and beta 2-adrenoceptor agonists applied into the hypothalamic paraventricular nuclei of spontaneously hypertensive rats on urine production. Tsushima H, etal., Jpn J Pharmacol. 1994 Mar;64(3):201-7.
130. Direct inotropic effect of the beta-2 receptor agonist terbutaline on impaired diaphragmatic contractility in septic rats. Uzuki M, etal., Heart Lung. 2007 Mar-Apr;36(2):140-7.
131. Polymorphisms of the beta2 adrenoreceptor gene in chronic obstructive pulmonary disease. Vacca G, etal., Ther Adv Respir Dis. 2009 Feb;3(1):3-10.
132. Progesterone transcriptionally regulates the beta 2-adrenergic receptor gene in pregnant rat myometrium. Vivat V, etal., J Biol Chem. 1992 Apr 25;267(12):7975-8.
133. Autoantibodies to beta 2-adrenergic receptors with antiadrenergic activity from patients with allergic asthma. Wallukat G and Wollenberger A, J Allergy Clin Immunol. 1991 Oct;88(4):581-7.
134. Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. Wang D, etal., FASEB J. 2010 Sep;24(9):3511-21. doi: 10.1096/fj.10-156661. Epub 2010 Apr 15.
135. Association of the beta2-adrenergic receptor gene with essential hypertension in the non-Han Chinese Yi minority human population. Wu H, etal., J Hypertens. 2006 Jun;24(6):1041-7.
136. beta2-adrenergic receptor gene polymorphisms in myasthenia gravis (MG). Xu BY, etal., Clin Exp Immunol. 2000 Jan;119(1):156-60.
137. Transcriptional and posttranscriptional regulation of beta(2)-adrenergic receptor gene in rat liver during sepsis. Yang J, etal., Am J Physiol. 1999 Jul;277(1 Pt 2):R132-9.
138. Haplotype analysis of the beta2 adrenergic receptor gene and risk of myocardial infarction in humans. Zee RY, etal., Genetics. 2005 Mar;169(3):1583-7. Epub 2004 Nov 1.
139. Anti-inflammatory effects of formoterol and ipratropium bromide against acute cadmium-induced pulmonary inflammation in rats. Zhang W, etal., Eur J Pharmacol. 2010 Feb 25;628(1-3):171-8. Epub 2009 Nov 24.
140. Enhanced cardiac L-type calcium current response to beta2-adrenergic stimulation in heart failure. Zhang ZS, etal., J Pharmacol Exp Ther. 2001 Jul;298(1):188-96.
141. [Expression and significance of beta(2)-adrenoreceptor in inflammatory cells of patients with chronic obstructive pulmonary disease] Zhu WJ, etal., Zhonghua Yi Xue Za Zhi. 2008 Aug 5;88(30):2099-102.
Additional References at PubMed
PMID:2155412   PMID:2834198   PMID:6321299   PMID:7738011   PMID:8308019   PMID:8597598   PMID:8693001   PMID:9235896   PMID:9305915   PMID:10358008   PMID:10358009   PMID:10753752  
PMID:11214319   PMID:11557593   PMID:11577089   PMID:11641423   PMID:12297500   PMID:12477932   PMID:12925702   PMID:14625387   PMID:15016730   PMID:15123695   PMID:15162487   PMID:15518545  
PMID:15592462   PMID:15724149   PMID:15791602   PMID:15993847   PMID:17119919   PMID:17158652   PMID:17629454   PMID:17671986   PMID:17828453   PMID:17911346   PMID:18006556   PMID:18154937  
PMID:18177419   PMID:18296565   PMID:18396264   PMID:18408128   PMID:18469068   PMID:18487315   PMID:18583384   PMID:18680159   PMID:18696115   PMID:18838481   PMID:19120131   PMID:19120133  
PMID:19581316   PMID:19710023   PMID:19763081   PMID:19801680   PMID:20033361   PMID:20087285   PMID:20132410   PMID:20382857   PMID:20417717   PMID:20547682   PMID:20590567   PMID:20602544  
PMID:20607388   PMID:20637865   PMID:20729750   PMID:21054861   PMID:21220710   PMID:21466811   PMID:21752065   PMID:21777029   PMID:21787468   PMID:21914456   PMID:21954875   PMID:22036623  
PMID:22099178   PMID:22216755   PMID:22242170   PMID:22248722   PMID:22270541   PMID:22457517   PMID:22564389   PMID:22732314   PMID:23166351   PMID:23174211   PMID:23343624   PMID:23373597  
PMID:23382219   PMID:23418295   PMID:23708524   PMID:24032709   PMID:24037783   PMID:24412308   PMID:24727346   PMID:24831005   PMID:24836853   PMID:25209288   PMID:25211146   PMID:25556934  
PMID:26248277   PMID:26399643   PMID:26426856   PMID:27035432   PMID:27234170   PMID:27402767   PMID:28160015   PMID:28339772   PMID:28396116   PMID:28423616   PMID:28459158   PMID:28505272  
PMID:28754379   PMID:28820549   PMID:29030338   PMID:29208473   PMID:29212811   PMID:29478130   PMID:29733383   PMID:29973623   PMID:30054857   PMID:30165515   PMID:30836825   PMID:31730792  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21855,642,459 - 55,644,501 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1855,502,903 - 55,644,512 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1857,735,062 - 57,737,132 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01858,450,067 - 58,452,145 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01856,266,287 - 56,268,329 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01857,513,792 - 57,515,834 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1857,513,793 - 57,515,834 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01856,739,990 - 56,742,032 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41858,174,958 - 58,177,000 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11858,247,190 - 58,249,232 (-)NCBI
Celera1853,789,848 - 53,791,890 (-)NCBICelera
RH 3.4 Map18542.9RGD
Cytogenetic Map18q12.1NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh385148,826,611 - 148,828,623 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl5148,826,611 - 148,828,623 (+)EnsemblGRCh38hg38GRCh38
GRCh375148,206,174 - 148,208,186 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 365148,186,349 - 148,188,381 (+)NCBINCBI36Build 36hg18NCBI36
Build 345148,186,368 - 148,188,379NCBI
Celera5144,288,206 - 144,290,248 (+)NCBICelera
Cytogenetic Map5q32NCBI
HuRef5143,352,751 - 143,354,793 (+)NCBIHuRef
CHM1_15147,638,640 - 147,640,684 (+)NCBICHM1_1
T2T-CHM13v2.05149,361,444 - 149,363,456 (+)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm391862,310,784 - 62,313,052 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1862,310,887 - 62,313,030 (-)EnsemblGRCm39 Ensembl
GRCm381862,177,713 - 62,179,981 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1862,177,816 - 62,179,959 (-)EnsemblGRCm38mm10GRCm38
MGSCv371862,337,470 - 62,339,613 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361862,303,185 - 62,305,328 (-)NCBIMGSCv36mm8
Celera1863,462,804 - 63,464,949 (-)NCBICelera
Cytogenetic Map18E1NCBI
cM Map1835.1NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_0049554155,515,697 - 5,516,980 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049554155,515,157 - 5,517,198 (-)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan15142,203,567 - 142,333,375 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v05144,259,756 - 144,398,421 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.15150,267,321 - 150,269,339 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl5150,267,554 - 150,315,892 (+)Ensemblpanpan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.1460,048,502 - 60,050,447 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl459,941,517 - 60,050,298 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha459,812,943 - 59,814,888 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0460,537,283 - 60,539,228 (-)NCBIROS_Cfam_1.0
UMICH_Zoey_3.1460,317,278 - 60,319,223 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0460,444,286 - 60,446,231 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0460,962,485 - 60,964,430 (-)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_024407213144,411,444 - 144,414,154 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365045,985,960 - 5,987,210 (-)EnsemblSpeTri2.0
SpeTri2.0NW_0049365045,985,407 - 5,987,453 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl2150,033,579 - 150,040,731 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.12150,032,649 - 150,035,591 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.12351,445,920 - 51,447,942 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl2351,446,154 - 51,447,401 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366603426,307,284 - 26,309,305 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_0046247748,211,984 - 8,213,240 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046247748,211,723 - 8,215,962 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Adrb2
4 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:42
Count of miRNA genes:41
Interacting mature miRNAs:42
Prediction methods:Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
2299160Iddm35Insulin dependent diabetes mellitus QTL 352.79blood glucose amount (VT:0000188)age at onset/diagnosis of type 1 diabetes mellitus (CMO:0001140)18420794160377792Rat
2293708Bss46Bone structure and strength QTL 468.80.0001lumbar vertebra morphology trait (VT:0010494)lumbar vertebra cortical cross-sectional area (CMO:0001690)181179151863636873Rat
1578661Bss20Bone structure and strength QTL 203.7femur morphology trait (VT:0000559)femoral neck cross-sectional area (CMO:0001697)181179151883218561Rat
1578667Bss21Bone structure and strength QTL 213.5femur morphology trait (VT:0000559)femoral neck cortical cross-sectional area (CMO:0001702)181179151883218561Rat
1358358Sradr6Stress Responsive Adrenal Weight QTL 62.49adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)181194429959330563Rat
6903359Bp355Blood pressure QTL 3553.6arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)181194454459796478Rat
2313082Bss85Bone structure and strength QTL 850.80.0001long bone metaphysis morphology trait (VT:0000133)tibia midshaft total cross-sectional area (CMO:0001715)181495133759951337Rat
1358193Emca2Estrogen-induced mammary cancer QTL 21.6mammary gland integrity trait (VT:0010552)post-insult time to mammary tumor formation (CMO:0000345)181800759963571040Rat
1600373Mamtr6Mammary tumor resistance QTL 6mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)181927890183218561Rat
1331741Bp232Blood pressure QTL 2323.59112arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)182137289383213037Rat
1331733Bp233Blood pressure QTL 2333.97196arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)182479697779788953Rat
2325839Bp348Blood pressure QTL 3480.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)182557098570570985Rat
2293704Bss35Bone structure and strength QTL 354.590.0002femur strength trait (VT:0010010)femur midshaft polar moment of inertia (CMO:0001669)182896485373964853Rat
2300157Bmd66Bone mineral density QTL 6613.10.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)182896485373964853Rat
2300177Bmd65Bone mineral density QTL 6519.70.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)182896485373964853Rat
9589816Gluco68Glucose level QTL 687.250.001blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)182979296574792965Rat
8694378Bw157Body weight QTL 1573.590.001body lean mass (VT:0010483)lean tissue morphological measurement (CMO:0002184)182979296574792965Rat
9590318Scort22Serum corticosterone level QTL 227.640.001blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)182979296574792965Rat
1331754Bp230Blood pressure QTL 2304.61609arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)182979296574792965Rat
738005Anxrr11Anxiety related response QTL 113.4exploratory behavior trait (VT:0010471)number of entries into a discrete space in an experimental apparatus (CMO:0000960)183003981375039813Rat
61383Bp47Blood pressure QTL 4717.3arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)183127168160377755Rat
1331742Bp228Blood pressure QTL 2283.88752arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135940859796643Rat
1331774Bp226Blood pressure QTL 2264.41065arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135940859796643Rat
1331776Bp225Blood pressure QTL 2252.829arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)183135940859796643Rat
1331798Bp224Blood pressure QTL 2243.53873arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135940859796643Rat
1331727Bp237Blood pressure QTL 2373.053arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135940861698465Rat
61429Cia17Collagen induced arthritis QTL 174.6joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)183135940870263868Rat
2303120Mamtr8Mammary tumor resistance QTL 80.001mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)183135940883218561Rat
6903347Bp350Blood pressure QTL 3504.4arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135953059796478Rat
631274Sprol1Serum protein level QTL 15.3blood total protein amount (VT:0005567)serum total protein level (CMO:0000661)183139332077209694Rat
631518Bw11Body weight QTL 112.8body mass (VT:0001259)body weight (CMO:0000012)183587072380870723Rat
61367Iddm4Insulin dependent diabetes mellitus QTL 42.330.0074blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)183819245583192455Rat
1598826Anxrr20Anxiety related response QTL 203.04body movement coordination trait (VT:0005424)number of rearing movements in an experimental apparatus (CMO:0001752)184143297183828827Rat
6893683Bw110Body weight QTL 1102.70.002body mass (VT:0001259)body weight (CMO:0000012)184334502283828827Rat
8694366Abfw8Abdominal fat weight QTL 86.380.001visceral adipose mass (VT:0010063)abdominal fat pad weight to body weight ratio (CMO:0000095)184664067583828827Rat
8694432Bw165Body weight QTL 1653.810.001body lean mass (VT:0010483)lean tissue morphological measurement (CMO:0002184)184664067583828827Rat
9589041Epfw12Epididymal fat weight QTL 1217.080.001epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)184664067583828827Rat
1331806Bp229Blood pressure QTL 2294.36484arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671876357867167Rat
1331736Bp227Blood pressure QTL 2272.791arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)184671876359796643Rat
1331780Bp238Blood pressure QTL 2383.269arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671876359796643Rat
6903345Bp349Blood pressure QTL 3493.9arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671893559796478Rat
6903349Bp351Blood pressure QTL 3513.5arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671893559796478Rat
6903351Bp352Blood pressure QTL 3523.3arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671893559796478Rat
61360EaeyExperimental allergic encephalomyelitis QTL y3nervous system integrity trait (VT:0010566)experimental autoimmune encephalomyelitis duration (CMO:0001424)184698893960377753Rat
2303571Bw92Body weight QTL 923body mass (VT:0001259)body weight (CMO:0000012)184852004483828827Rat
2303584Gluco55Glucose level QTL 552blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)184852004483828827Rat
7411719Strs5Sensitivity to stroke QTL 59.4cerebrum integrity trait (VT:0010549)percentage of study population developing cerebrovascular lesions during a period of time (CMO:0000932)184999995865845095Rat
2293658Bmd23Bone mineral density QTL 237.30.0001femur mineral mass (VT:0010011)total volumetric bone mineral density (CMO:0001728)185146473363636873Rat
738008Hcar14Hepatocarcinoma resistance QTL 144.3liver integrity trait (VT:0010547)liver nonremodeling tumorous lesion number (CMO:0001462)185146473383218561Rat
1331730Scl27Serum cholesterol level QTL 273.826blood HDL cholesterol amount (VT:0000184)serum high density lipoprotein cholesterol level (CMO:0000361)185229287559796643Rat
1331752Bw27Body weight QTL 272.963body mass (VT:0001259)body weight (CMO:0000012)185229287565845095Rat
1359020Ppulsi2Prepulse inhibition QTL 22.71prepulse inhibition trait (VT:0003088)acoustic startle response measurement (CMO:0001519)185229287573997283Rat
1600375Mcs22Mammary carcinoma susceptibility QTL 223.3mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)185253976363933058Rat
631509Sald2Serum aldosterone level QTL 22.9blood aldosterone amount (VT:0005346)serum aldosterone level (CMO:0000487)185253976369140759Rat
12880368Bw187Body weight QTL 1870.045body mass (VT:0001259)body weight (CMO:0000012)185253976376104388Rat
12904067Cm122Cardiac mass QTL 1220.001heart mass (VT:0007028)heart wet weight to body weight ratio (CMO:0002408)185253976376104388Rat
12904069Cm123Cardiac mass QTL 1230.001heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)185253976376104388Rat
12904070Cm124Cardiac mass QTL 1240.01heart right ventricle mass (VT:0007033)heart right ventricle weight to body weight ratio (CMO:0000914)185253976376104388Rat
12904071Am18Aortic mass QTL 180.001aorta mass (VT:0002845)aorta weight to aorta length to body weight ratio (CMO:0002722)185253976376104388Rat
12904073Kidm71Kidney mass QTL 710.001kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)185253976376104388Rat
2301417Bp319Blood pressure QTL 3190.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)185253976376104388Rat
1300125Rf26Renal function QTL 263.2urine potassium amount (VT:0010539)urine potassium excretion rate (CMO:0000761)185253986365844950Rat
1298072Cia26Collagen induced arthritis QTL 263.6joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)185470976983828827Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21855,642,607 - 55,642,948 (+)MAPPERmRatBN7.2
Rnor_6.01857,513,941 - 57,514,281NCBIRnor6.0
Rnor_5.01856,740,139 - 56,740,479UniSTSRnor5.0
RGSC_v3.41858,175,106 - 58,175,447RGDRGSC3.4
RGSC_v3.41858,175,107 - 58,175,447UniSTSRGSC3.4
RGSC_v3.11858,247,338 - 58,247,679RGD
Celera1853,789,997 - 53,790,337UniSTS
RH 3.4 Map18542.0UniSTS
RH 3.4 Map18542.0RGD
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21855,642,728 - 55,643,097 (+)MAPPERmRatBN7.2
Rnor_6.01857,514,062 - 57,514,430NCBIRnor6.0
Rnor_5.01856,740,260 - 56,740,628UniSTSRnor5.0
RGSC_v3.41858,175,227 - 58,175,596RGDRGSC3.4
RGSC_v3.41858,175,228 - 58,175,596UniSTSRGSC3.4
RGSC_v3.11858,247,459 - 58,247,828RGD
Celera1853,790,118 - 53,790,486UniSTS
SHRSP x BN Map1823.9899UniSTS
SHRSP x BN Map1823.9899RGD
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21855,642,990 - 55,643,374 (+)MAPPERmRatBN7.2
Rnor_6.01857,514,324 - 57,514,707NCBIRnor6.0
Rnor_5.01856,740,522 - 56,740,905UniSTSRnor5.0
RGSC_v3.41858,175,490 - 58,175,873UniSTSRGSC3.4
Celera1853,790,380 - 53,790,763UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21855,645,233 - 55,645,438 (+)MAPPERmRatBN7.2
Rnor_6.01857,516,567 - 57,516,771NCBIRnor6.0
Rnor_5.01856,742,765 - 56,742,969UniSTSRnor5.0
RGSC_v3.41858,177,733 - 58,177,937UniSTSRGSC3.4
Celera1853,792,623 - 53,792,827UniSTS
RH 3.4 Map18543.8UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21855,642,580 - 55,642,750 (+)MAPPERmRatBN7.2
Rnor_6.01857,513,914 - 57,514,083NCBIRnor6.0
Rnor_5.01856,740,112 - 56,740,281UniSTSRnor5.0
RGSC_v3.41858,175,080 - 58,175,249UniSTSRGSC3.4
Celera1853,789,970 - 53,790,139UniSTS
RH 3.4 Map18542.9UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21855,645,582 - 55,645,715 (+)MAPPERmRatBN7.2
Rnor_6.01857,516,916 - 57,517,048NCBIRnor6.0
Rnor_5.01856,743,114 - 56,743,246UniSTSRnor5.0
RGSC_v3.41858,178,082 - 58,178,214UniSTSRGSC3.4
Celera1853,792,972 - 53,793,104UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21855,642,580 - 55,642,746 (+)MAPPERmRatBN7.2
Rnor_6.01857,513,914 - 57,514,079NCBIRnor6.0
Rnor_5.01856,740,112 - 56,740,277UniSTSRnor5.0
RGSC_v3.41858,175,080 - 58,175,245UniSTSRGSC3.4
Celera1853,789,970 - 53,790,135UniSTS
RH 3.4 Map18542.1UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21855,642,995 - 55,643,113 (+)MAPPERmRatBN7.2
Rnor_6.01857,514,329 - 57,514,446NCBIRnor6.0
Rnor_5.01856,740,527 - 56,740,644UniSTSRnor5.0
RGSC_v3.41858,175,495 - 58,175,612UniSTSRGSC3.4
Celera1853,790,385 - 53,790,502UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21855,643,431 - 55,643,886 (+)MAPPERmRatBN7.2
Rnor_6.01857,514,765 - 57,515,219NCBIRnor6.0
Rnor_5.01856,740,963 - 56,741,417UniSTSRnor5.0
RGSC_v3.41858,175,931 - 58,176,385UniSTSRGSC3.4
Celera1853,790,821 - 53,791,275UniSTS
Cytogenetic Map18q12.1UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21855,643,288 - 55,644,176 (+)MAPPERmRatBN7.2
Rnor_6.01857,514,622 - 57,515,509NCBIRnor6.0
Rnor_5.01856,740,820 - 56,741,707UniSTSRnor5.0
RGSC_v3.41858,175,788 - 58,176,675UniSTSRGSC3.4
Celera1853,790,678 - 53,791,565UniSTS
Cytogenetic Map18q12.1UniSTS


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 12 12 6 12 2 10
Low 3 39 42 26 13 26 8 11 66 35 34 1 8
Below cutoff 4 3 3 3 8 5


RefSeq Acc Id: ENSRNOT00000026098   ⟹   ENSRNOP00000026098
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1855,502,903 - 55,644,512 (-)Ensembl
Rnor_6.0 Ensembl1857,513,793 - 57,515,834 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000101212   ⟹   ENSRNOP00000086275
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1855,573,898 - 55,644,512 (-)Ensembl
RefSeq Acc Id: NM_012492   ⟹   NP_036624
RefSeq Status: VALIDATED
Rat AssemblyChrPosition (strand)Source
mRatBN7.21855,642,459 - 55,644,501 (-)NCBI
Rnor_6.01857,513,792 - 57,515,834 (-)NCBI
Rnor_5.01856,739,990 - 56,742,032 (-)NCBI
RGSC_v3.41858,174,958 - 58,177,000 (-)RGD
Celera1853,789,848 - 53,791,890 (-)RGD
RefSeq Acc Id: NP_036624   ⟸   NM_012492
- UniProtKB: Q6LCR3 (UniProtKB/Swiss-Prot),   P10608 (UniProtKB/Swiss-Prot),   Q8VBU7 (UniProtKB/TrEMBL),   D7NIV9 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000026098   ⟸   ENSRNOT00000026098
RefSeq Acc Id: ENSRNOP00000086275   ⟸   ENSRNOT00000101212
Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P10608-F1-model_v2 AlphaFold P10608 1-418 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2060 AgrOrtholog
BioCyc Gene G2FUF-7294 BioCyc
Ensembl Genes ENSRNOG00000019217 Ensembl, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000026098.2 UniProtKB/TrEMBL
  ENSRNOP00000086275.1 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000026098.4 UniProtKB/TrEMBL
  ENSRNOT00000101212.1 UniProtKB/TrEMBL
Gene3D-CATH Rhodopsin 7-helix transmembrane proteins UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro ADR_fam UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ADRB2_rcpt UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  GPCR_Rhodpsn UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  GPCR_Rhodpsn_7TM UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:24176 UniProtKB/TrEMBL
  PTHR24248:SF21 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam 7tm_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Adrb2 PhenoGen
  ADRENRGCB2AR UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  G_PROTEIN_RECEP_F1_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
SMART 7TM_GPCR_Srsx UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP Family A G protein-coupled receptor-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0A8I6A0X2_RAT UniProtKB/TrEMBL
  ADRB2_RAT UniProtKB/Swiss-Prot
  Q99P02_RAT UniProtKB/TrEMBL
UniProt Secondary Q6LCR3 UniProtKB/Swiss-Prot

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2015-12-02 Adrb2  adrenoceptor beta 2  Adrb2  adrenoceptor beta 2, surface  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2012-07-13 Adrb2  adrenoceptor beta 2, surface  Adrb2  adrenergic, beta-2-, receptor, surface  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-09-25 Adrb2  adrenergic, beta-2-, receptor, surface  Adrb2  adrenergic receptor, beta 2  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2002-11-06 Adrb2  adrenergic receptor, beta 2    Adrenergic, beta 2-, receptor, surface  Name updated 625702 APPROVED
2002-06-10 Adrb2  Adrenergic, beta 2-, receptor, surface      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_expression mRNA expressed in heart 632159
gene_function binds adrenergic receptor agonist zinterol 632158
gene_homology has similarity to the cardiac muscarinic cholinergic receptor Chrm2 632159
gene_process mediates G-protein coupled regulation of calcium channel current 632158
gene_protein 418 amino acid protein, 46.89 kDa protein 632159